000			02231ngm a2200457 a 4500
001			HST3769
003			UkLoHST
006			m c
007			cr|cna|||a||||
007			vz|czazum
008			140722s2014 enk|||||||||||s|||v|eng d
028	5	0	_a3769 _bHenry Stewart Talks
035			_a(UkLoHST)2830
040			_aUkLoHST _beng _cUkLoHST
100	1		_aCenci, Angela, _u(University of Lund, Sweden) _4spk
245	1	0	_aMechanisms of L-DOPA-induced dyskinesia in Parkinson's disease _h[electronic resource] / _cAngela Cenci.
246	3		_aMechanisms of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in Parkinson's disease
260			_aLondon : _bHenry Stewart Talks, _c2014.
300			_a1 online resource (1 streaming video file (44 min.) : _bcolor, sound).
490	1		_aParkinson's disease, _x2056-452X
500			_aAnimated audio-visual presentation with synchronized narration.
500			_aTitle from title frames.
505	0		_aContents: Characteristics of Parkinson´s disease (PD) -- Dysregulation of dopamine release and re-uptake in the striatum -- L-DOPA as a drug for PD -- L-DOPA-induced dyskinesia (LID) -- Pre- and post-synaptic mechanisms of LID -- Serotonin neurons, dopamine and LID -- Genes linked to involuntary movements (ΔFosB, ERK1/2, mGluR5) -- Spiny projection neurons (SPNs) in PD and LID.
506			_aAccess restricted to subscribers.
538			_aMode of access: World Wide Web.
650		0	_aAntiparkinsonian agents _xSide effects.
650		0	_aDopa _xPhysiological effect.
650		0	_aParkinson's disease _xChemotherapy.
650		0	_aParkinson's disease _xTreatment.
650		2	_aAntiparkinson Agents _xtherapeutic use.
650		2	_aAntiparkinson Agents _xtoxicity.
650		2	_aDyskinesia, Drug-Induced _xphysiopathology.
650		2	_aDyskinesia, Drug-Induced _xtherapy.
650		2	_aLevodopa _xtoxicity.
650		2	_aParkinson Disease _xdrug therapy.
650		2	_aParkinson Disease _xphysiopathology.
650		2	_aParkinson Disease _xtherapy.
830		0	_aHenry Stewart talks. _pBiomedical & life sciences collection. _pParkinson's disease.
856	4	0	_uhttps://hstalks.com/bs/2830/
856	4	2	_uhttps://hstalks.com/bs/p/805/ _3Series
999			_c77059 _d77059